Lubiprostone Drug Asset Due Diligence Report 2026

This Lubiprostone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lubiprostone can convert its Small molecule drug profile and CLCN2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lubiprostone (query alias: lubiprostone)
Modality / target	Small molecule drug; CLCN2; CLCN2 agonists
Highest global status	Approved
Originator	Sucampo Pharmaceuticals LLC
Active developers	Viatris Pharmaceutical GK, Mylan LLC, Sucampo Pharma Americas LLC

The MCP disease footprint includes Opioid-Induced Constipation, Chronic constipation, Irritable bowel syndrome with constipation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600127325	Phase 4	Not yet recruiting	244	Incidence of constipation during chemotherapy
NCT07277907	Phase 3	Recruiting	346	The change in spontaneous bowel movements (SBMs) frequency from baseline during the first week
NCT07405736	Phase 2	Not yet recruiting	124	1-year Progression-Free Survival (PFS) Rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

EFFICACY OF LUBIPROSTONE FOR TREATMENT OF CHILDHOODFUNCTIONAL CONSTIPATION: AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL

Not Applicable; n=277; evaluation: Positive. Reported fields: SBM = 2.7 motions/week ( 1.04); SBM = 4.78 motions/week ( 0.99)

Lubiprostone Plus Polyethylene Glycol-electrolyte Solutionvs. Placebo Plus Polyethylene Glycol-electrolyte Solution for Outpatient Colonoscopy Preparation: A Randomized, Double-blind, Placebo-controlled Trial

Phase 4; n=158; evaluation: not stated. Reported fields: Endoscopist Evaluation of Colon Cleanliness in the Lubiprostone Group vs the Placebo Group(Mean): P-Value = 0.05; Endoscopist Evaluation of Colon Cleanliness in the Lubiprostone Group vs the Placebo Group(Mean): P-Value = 0.05; Endoscopist Evaluation of Colon Cleanliness in the Lubiprostone Group vs the Placebo Group(Mean): P-Value = 0.05

Safety of Lubiprostone in Pediatric Patients With Functional Constipation: A Nonrandomized, Open-Label Trial

Phase 3; n=87; evaluation: Positive. Reported fields: TEAE = TEAEs were mostly mild in intensity, with gastrointestinal disorders (diarrhea, vomiting) most frequently reported. ; TEAE = TEAEs were mostly mild in intensity, with gastrointestinal disorders (diarrhea, vomiting) most frequently reported. ; TEAE = TEAEs were mostly mild in intensity, with gastrointestinal disorders (diarrhea, vomiting) most frequently reported.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lubiprostone addresses Opioid-Induced Constipation, Chronic constipation, Irritable bowel syndrome with constipation. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2015-05-13	哈尔滨誉衡药业股份有限公司关于与Sucampo AG（苏坎波公司）签订《鲁比前列酮中国地区独家许可、开发、商业化及供货协议》的公告	Approved	US$1.0M upfront; US$0.5M milestones
2014-10-21	Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)	Approved	US$14.0M upfront; US$35.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “鲁比前列酮(LUBIPROSTONE)的制备方法和其中间物”. The milestone feed surfaced a patent-application signal described as “Analysis method for determining lubiprostone test sample related substances”. The milestone feed surfaced a patent-application signal described as “Analysis method for determining lubiprostone test sample related substances”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO